¿ Amarillo Biosciences Inc., of Amarillo, Texas, said enrollment began at three additional sites for its Phase II trial of low-dose interferon for fibromyalgia syndrome.
¿ Atrix Laboratories Inc., of Fort Collins, Colo., received marketing approval in the U.K. for Atridox (doxycycline) 8.5 percent, a site-specific antibiotic for treating periodontal disease.
¿ Biogen Inc., of Cambridge, Mass., received the National Medal of Technology, an award bestowed by the government to those developing innovative technologies. Biogen was selected based on the biology breakthroughs it made in developing important pharmaceutical products. President Bill Clinton presented the medal.
¿ BioLabs Inc., of New York, said Biotherapies Inc., in which it has an equity position, received approval to begin Phase I and II trials of mammastatin to treat breast cancer. The human mammary epithelial cell-derived product will be used as a replacement therapy in refractory Stage IV patients.
¿ Cephalon Inc., of West Chester, Pa., began studies in the U.S. and U.K. to evaluate the safety and efficacy of Provigil to treat excessive sleepiness associated with obstructive sleep apnea. The U.S study will include 150 patients and the U.K. study 40. Both are randomized, placebo-controlled, double-blind trials. Provigil already is approved in both the U.S. and U.K. for daytime sleepiness associated with narcolepsy.
¿ Cypros Pharmaceutical Corp., of Carlsbad, Calif., received a $750,000 Phase II small business innovation research grant from the National Institutes of Health to fund development of its compounds to protect the brain from ischemic injury. The company¿s agents are designed to block the release of excitotoxins and glutamic and aspartic acid from glial cells in the brain.
¿ INSMED Pharmaceuticals Inc., of Richmond, Va., said data published in the April 29, 1999, issue of the New England Journal of Medicine showed its lead product, INS-1, significantly improved ovulation rates while decreasing total testosterone in women with polycystic ovary syndrome. It also reduced triglycerides and blood pressure.
¿ Isis Pharmaceuticals Inc., of Carlsbad, Calif., and Ciba Vision Corp., a division of Basel, Switzerland-based Novartis AG, received a positive recommendation in Europe on its marketing authorization application for Vitravene for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Vitravene, an antisense inhibitor of CMV, is approved in the U.S.
¿ Micrologix Biotech Inc., of Vancouver, British Columbia, completed a two-part Phase I trial of MBI 226, a Bactolysin drug candidate for preventing bloodstream infections in patients undergoing central venous catheterization. The study showed the agent was safe and eliminated 99.9 percent of bacteria commonly found on the skin, and that it prevented bacterial growth on catheters. The company hopes to move into Phase II later this year.
¿ Ortec International Inc., of New York, extended the expiration date on its Class B warrants to Nov. 30, 1999, from May 28. The callable warrants have a $15 exercise price. There are nearly 1.2 million outstanding. The warrants were part of the company¿s January 1996 initial public offering.
¿ StressGen Biotechnologies Corp., of Victoria, British Columbia, opened an office in Collegeville, Pa. It will be used for various corporate, clinical and regulatory activities.